Journal
DISEASE MODELS & MECHANISMS
Volume 11, Issue 9, Pages -Publisher
COMPANY BIOLOGISTS LTD
DOI: 10.1242/dmm.034801
Keywords
Drug discovery; Fatty liver disease; Idebenone; Nuclear receptors; Zebrafish
Categories
Funding
- Canadian Institutes of Health Research (CIHR) [MOP 133473]
- CIHR [OME-142884]
- Natural Sciences and Engineering Research Council of Canada [RGPIN 03666-14]
- Ontario Centres of Excellence [22096]
- CQDM [OME-142884]
Ask authors/readers for more resources
Current peroxisome proliferator-activated receptor (PPAR)-targeted drugs, such as the PPAR gamma-directed diabetes drug rosiglitazone, are associated with undesirable side effects due to robust agonist activity in non-target tissues. To find new PPAR ligands with fewer toxic effects, we generated transgenic zebrafish that can be screened in high throughput for new tissue-selective PPAR partial agonists. A structural analog of coenzyme Q(10) (idebenone) that elicits spatially restricted partial agonist activity for both PPAR alpha and PPAR gamma was identified. Coenzyme Q(10) was also found to bind and activate both PPARs in a similar fashion, suggesting an endogenous role in relaying the states of mitochondria, peroxisomes and cellular redox to the two receptors. Testing idebenone in a mouse model of type 2 diabetes revealed the ability to reverse fatty liver development. These findings indicate new mechanisms of action for both PPAR alpha and PPAR gamma, and new potential treatment options for nonalcoholic fatty liver disease (NAFLD) and steatosis. This article has an associated First Person interview with the first author of the paper.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available